Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
19 hedge funds and large institutions have $2.85M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 6 closing their positions.
21% less funds holding
Funds holding: 24 → 19 (-5)
52% less capital invested
Capital invested by funds: $6M → $2.85M (-$3.15M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$441K |
| 2 |
LPL Financial
San Diego,
California
|
+$37.2K |
| 3 |
BHWM
Beaird Harris Wealth Management
Dallas,
Texas
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$865K |
| 3 |
Goldman Sachs
New York
|
-$767K |
| 4 |
Jane Street
New York
|
-$265K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$45.5K |
GERM Hedge Fund Activity: Q1 2023 in Review
19 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q1 2023, worth a combined $2.85M — down 52% from $6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GERM and 1 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was International Assets Investment Management, opening a new position worth an estimated $441K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.1M sold.
- 19 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $2.85M of Amplify Treatments, Testing and Advancements ETF stock for Q1 2023, down 52% quarter-over-quarter.
- 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q1 2023 and 6 closed out, a net change of -5 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q1 2023 was International Assets Investment Management, an estimated $441K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q1 2023 was Susquehanna International Group, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2023.